Reckitt Benckiser announced last weekend that it is selling its Mead Johnson Nutrition company in China to Primavera Capital Group. The deal was said to be valued at $2.2 billion.
As per Reuters, while Primavera Capital has already bought Reckitt Benckiser’s infant formula and child nutrition business in China, the latter will still retain an eight percent stake in the China unit of Mead Johnson Nutrition.
Reckitt to incur a loss on the sale
Reckitt Benckiser is expecting to receive around $1.3 billion from the sale, but it is also anticipating a net loss of $3.5 billion on the disposal. The loss is said to be due to intangible assets and re-measurement of goodwill.
In any case, it was in March when it was first reported that Reckitt Benckiser was considering the sale of the Chinese unit of Mead Johnson. The company observed a sluggish sale and launched a strategic review of its infant formula and child nutrition business in China.
In the end, the sale was decided as sales are not going up anywhere, and Reckitt cited the intense competition with local baby formula brands as one of the reasons for the slow income. Also, the low birth rates in China was also blamed for the dwindling sales as there are fewer babies to feed with the infant formula.
The deal between Reckitt and Primavera
As the sale was revealed, Reckitt Beckinser shared that the deal with Primavera Capital includes the sale of the company’s production factories in Guangzhou, China, and at Nijmegen in the Netherlands. Moreover, a royalty-free perpetual and exclusive license of Mead Johnson and Enfa brands in China, including Enfagrow, Enfamil, and Enfinitas, are also included in the agreement.
Then again, it should be noted that this is only in Greater China, as Reckitt still owns and will continue to sell Mead Johnson and Enfa products in other parts of the world.
"We are pleased to acquire the Greater China business of Mead Johnson, a long-established and renowned multinational infant and children nutrition brand,” Primavera Capital Group founder and chairman, Dr. Fred Hu, said in a press release. “As the controlling shareholder, Primavera is committed to serve tens of millions of Chinese mothers and babies and safeguard their well-being.”
Finally, the Reckitt Beckinser and Primavera Capital deal is expected to close within the second half of this year.


How the war in Iran is already affecting UK farmers and food production
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025
Gold Prices Climb as Middle East Ceasefire Talks Stir Market Optimism
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained
U.S. Stock Futures Steady as Iran Reviews U.S. Ceasefire Proposal
Oil Prices Climb as Iran Reviews U.S. Peace Proposal Amid Middle East Tensions
Oil Prices Slip as Trump Extends Iran Ceasefire Deadline Amid Ongoing War Fears
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Google's TurboQuant Sends South Korean Chip Stocks Tumbling Amid AI Memory Demand Fears
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 



